Please assess the completion status of the following clinical trial:

Trial Title: V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese females~* Not pregnant at Screening and agree to use effective contraception through Month 7 of the study~* Lifetime history of 0 to 4 male or female sexual partners~* No oral temperature ≥37.5 centigrade within 24 hours prior to injection~Exclusion Criteria:~* Received a marketed HPV vaccine~* Prior abnormal Papanicolaou smear (PAP) or biopsy showing CIN~* Known history of positive test for HPV~* Known history of genital warts~* Received immune globulin or blood products within 6 months prior to first injection or plan to receive any through Month 7 of the study~* History of splenectomy, known immune disorders, or receiving immunosuppressives~* Immunocompromised or diagnosed as having human immunodeficiency virus (HIV)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).